Bristol Reyataz To Launch In July; Lipid Data Included In Labeling
Executive Summary
Bristol-Myers Squibb will make Reyataz (atazanavir) available in July following the June 20 approval of the HIV treatment
You may also be interested in...
Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Prescriptions for Abbott's protease inhibitor Kaletra are outpacing the product's sales growth
Kaletra Scripts Outpace Sales; Abbott Expects 10% Sales Growth
Prescriptions for Abbott's protease inhibitor Kaletra are outpacing the product's sales growth
Bristol Reyataz Dosing For Renally-Impaired Patients Will Be Phase IV Study
FDA is requesting that Bristol-Myers Squibb determine appropriate Reyataz dosing for patients with renal impairment in a Phase IV study